PubMed چکیده/رکورد

Mitochondrial guardian and therapeutic target: The promise of TFAM in acute kidney injury.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

Acute kidney injury (AKI) is a clinically significant syndrome characterized by rapid deterioration of renal function. Despite its complex and multifactorial pathogenesis, effective targeted therapies remain scarce. Mitochondrial dysfunction is increasingly recognized as a central driver of AKI progression. Mitochondrial transcription factor A (TFAM), a nucleus-encoded protein that governs mitochondrial DNA (mtDNA) maintenance, transcription and replication, plays an essential role in preserving mitochondrial integrity and biogenesis. This review systematically synthesizes current knowledge on TFAM biology, with a focus on its structural features, regulatory networks, and dynamic changes in the context of AKI. We integrate evidence showing that TFAM upregulation, whether through pharmacological interventions or genetic manipulation, consistently protects against tubular cell injury, preserves mitochondrial function, and attenuates inflammation across diverse AKI models. By providing a conceptual framework that links TFAM's molecular functions to its pathophysiological roles in the kidney, this review highlights TFAM as a promising therapeutic node. We also identify key knowledge gaps and propose future research directions to facilitate the translation of TFAM-targeted strategies into clinical practice.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

Acute kidney injuryMitochondrial DNAMitochondrial dysfunctionMitochondrial transcription factor AOxidative stress
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2027

Robot-Assisted Partial Nephrectomy in a High-Complexity Renal Tumor in a Horseshoe Kidney.

INTRODUCTION: Horseshoe kidney is an uncommon congenital fusion anomaly that can make renal tumor surgery especially challenging because of altered rotation, limited mobility, variable vascular supply, and an unpredictable collecting system (1-7). This video presents a robot-assisted partial nephrectomy for a high-complexity renal tumor in this setting. CASE PRESENTATION: A 33-year-old man, with ECOG 0 and no relevant comorbidities, wa…

PubMed2026

Facilitators of Peer Support Among Patients With Chronic Kidney Disease: A Systematic Review and Qualitative Meta-Synthesis.

BACKGROUND: Patient-to-patient peer support has been identified as a promising approach for the management of chronic kidney disease and has been associated with improved clinical and psychosocial outcomes. Multiple factors may influence the implementation and effectiveness of peer support programs across different healthcare settings. OBJECTIVES: This qualitative meta-synthesis aimed to identify the key facilitators influencing peer s…

PubMed2026

Therapeutic efficacy of naloxone hydrochloride combined with hemoperfusion in toxic acute renal failure via the oxidative stress/Nrf2 pathway.

BACKGROUND: Toxic acute renal failure (ARF) involves severe oxidative stress. The Nrf2 pathway is a key antioxidant defense mechanism. OBJECTIVES: To investigate whether naloxone combined with hemoperfusion alleviates oxidative injury via Nrf2 activation in toxic ARF. METHODS: In this single-center retrospective cohort study at Qiqihar Medical University Hospital, 67 patients were enrolled through medical record screening. The control …

PubMed2026

A single-center retrospective cohort study of cinacalcet efficacy in uremic hemodialysis patients: Correlations with changes in parathyroid hormone, calcium and phosphorus over 12 months.

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a common complication in uremic hemodialysis patients, associated with disordered calcium (Ca) and phosphorus (P) metabolism. The long-term efficacy of cinacalcet (Cin) versus calcitriol (Cal) in achieving composite control of parathyroid hormone (iPTH) and Ca × P product remains unclear. OBJECTIVES: To compare the 12-month efficacy and safety of Cin versus Cal in treating SHPT and to…